ArriVent BioPharma heads into the week of May 18 carrying three fresh catalysts — a Q1 EPS miss, a $250 million at-the-market equity offering, and a Citigroup target cut — yet short sellers have been quietly reducing exposure even as the stock digests all three.
The short interest picture is the most notable feature right now. Bears have been covering steadily. Short interest as a percentage of the free float fell from roughly 24.3% on May 6 to 22.4% by May 12 — a 9.3% decline in shares short over the week and nearly 10% down over the month. That unwind stretches back further: shorts peaked near 27–28% of the float in late March and have been in retreat since. At 22.4% of float the position remains substantial, but the direction of travel is firmly toward lower conviction. Cost to borrow is correspondingly relaxed — below 1% annualised — and availability in the lending market is moderate, consistent with a short base that has room to exit but is not being squeezed. The ORTEX short score of 81.6, while elevated in absolute terms, has been drifting lower all week from a recent high of 83.
The announcement that drove Monday's session was the $250M ATM offering through Jefferies — a dilutive move that landed on the same day the company reported Q1 EPS of -$0.96, missing the -$0.86 consensus estimate. The stock fell about 1.8% on the day, a muted reaction relative to prior earnings swings. The March 5 print produced an 11.8% one-day decline and a further 9.3% drop over the following five days; the March 12 update carried a 2.9% one-day loss and a 7.1% five-day slide. By that comparison, the market treated May 11 relatively gently — which may partly explain why short sellers did not reload.
Options traders are reading the setup as firmly bullish rather than cautious. The put/call ratio is just 0.055 — well below the 20-day mean of 0.094 — and has been hovering near its lowest levels of the past year. That compares with a 52-week high PCR of 3.84, a reminder of how sharply sentiment has shifted. The lack of put demand is striking given the ATM dilution and earnings miss sitting in the rearview mirror; it suggests options participants are leaning into the pipeline story rather than hedging near-term downside.
The Street remains broadly constructive. Citigroup — one of the more active voices on this name — trimmed its target from $45 to $43 on May 13 while keeping its Buy rating. That follows a sharp raise in late April from $33 to $45, itself triggered by what appears to be positive pipeline newsflow. The mean analyst target of $41.94 implies roughly 45% upside to the current price of $28.97, and the bull case centres on firmonertinib's Phase 3 data in PACC-mutant lung cancer and an FDA IND clearance for ARR-002 in ovarian and endometrial cancers — the latter granted May 7. Bears point to commercial execution risk for firmonertinib, financing pressure (the ATM is the latest evidence), and competitive dynamics in EGFR-mutant NSCLC. The EPS surprise factor score ranks at the 68th percentile despite the Q1 miss, suggesting the track record on beats is stronger than this quarter's headline implies.
Institutional ownership is spread across specialist healthcare funds and index managers. Infinitum, Suvretta, and Hillhouse each hold roughly 8–9% of shares, and BlackRock and State Street have been modest buyers in recent months. The most current insider data runs to December 2025, when Hillhouse sold 555,555 shares at $23.37 — prior to the stock's subsequent rally — so the insider signal is stale and not informative for the current setup.
With a next event flagged for May 18, the next seven days will determine whether the ATM overhang weighs on the stock or whether fresh pipeline data absorbs the dilution. The relationship between short covering pace and the outcome of that catalyst is the key dynamic to track.
See the live data behind this article on ORTEX.
Open AVBP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
